PT - JOURNAL ARTICLE AU - Darcey, Valerie L. AU - Guo, Juen AU - Chi, Meible AU - Chung, Stephanie T. AU - Courville, Amber B. AU - Gallagher, Isabelle AU - Herscovitch, Peter AU - Howard, Rebecca AU - LaNoire, Melissa AU - Milley, Lauren AU - Schick, Alex AU - Stagliano, Michael AU - Turner, Sara AU - Urbanski, Nicholas AU - Yang, Shanna AU - Yim, Eunha AU - Zhai, Nan AU - Zhou, Megan S. AU - Hall, Kevin D. TI - Striatal dopamine tone is positively associated with body mass index in humans as determined by PET using dual dopamine type-2 receptor antagonist tracers AID - 10.1101/2023.09.27.23296169 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.27.23296169 4099 - http://medrxiv.org/content/early/2023/09/28/2023.09.27.23296169.short 4100 - http://medrxiv.org/content/early/2023/09/28/2023.09.27.23296169.full AB - The relationship between adiposity and dopamine type-2 receptor binding potential (D2BP) in the human brain has been repeatedly studied for >20 years with highly discrepant results, likely due to variable methodologies and differing study populations. We conducted a controlled inpatient feeding study to measure D2BP in the striatum using positron emission tomography with both [18F]fallypride and [11C]raclopride in pseudo-random order in 54 young adults with a wide range of body mass index (BMI 20-44 kg/m2). Within-subject D2BP measurements using the two tracers were moderately correlated (r=0.47, p<0.001). D2BP was negatively correlated with BMI as measured by [11C]raclopride (r= -0.51; p<0.0001) but not [18F]fallypride (r=-0.01; p=0.92) and these correlation coefficients were significantly different from each other (p<0.001). Given that [18F]fallypride has greater binding affinity to dopamine type-2 receptors than [11C]raclopride, which is more easily displaced by endogenous dopamine, our results suggest that adiposity is positively associated with increased striatal dopamine tone.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03648892Funding StatementThis study was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases and by the NIH Center on Compulsive Behaviors via the NIH Shared Resource Subcommittee.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the National Institute of Diabetes & Digestive & Kidney Diseases gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData reported in the present study are available upon reasonable request to the authors